Pavlo Kot

Kura Oncology sets investor webcast to discuss Caspian Therapeutics launch and KO-7246 preclinical data

Kura Oncology sets investor webcast to discuss Caspian Therapeutics launch and KO-7246 preclinical data
Kura Oncology hosts Caspian webcast

Kura Oncology has announced an investor webcast scheduled for October 13 at 4:30 p.m. ET to discuss the formation and launch of Caspian Therapeutics and to review preclinical data for KO-7246 presented at the 62nd EASD Annual Meeting.

The webcast will offer insights into Kura Oncology’s ongoing research and development efforts, particularly focused on menin-inhibitor therapies. The event reflects the company’s continued dedication to advancing its pipeline and sharing milestones with the investment community.

Kura Oncology recently launched Caspian Therapeutics to focus on small-molecule menin inhibitors targeting diabetes and cardiometabolic diseases. The company's leadership team was bolstered earlier this year when Jennifer Fulk was appointed as chief financial officer. These developments highlight ongoing changes to Kura Oncology’s strategic direction.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.